comprehensive -WSS

comprehensive

author：entertainment 2025-09-28 09:06:00 - browse：492

The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.

The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.

In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： New weight loss drugs vying to be the next Wegovy or Mounjaro

leisure time

WSS

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

The FDA weighs the risks of candy

Cassava reveals details — and problems — with Alzheimer's study

Meta's Zuckerberg and Chan on track to put $50 billion into science

WHO may add ‘noma' to its list of neglected tropical diseases

Telehealth options flood the market as retailers push virtual care

focus

comprehensive

entertainment

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

The cancer drug shortage isn’t new — and neither are the solutions

Testing for cancer recurrence creates a new limbo for patients

As demand for Covid shots wanes, Moderna seeks its next success

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Novavax promises a turnaround & Lilly roils the obesity market

The pink breast cancer awareness ribbon needs a redesign

How one medical school became remarkably diverse

Meta's Zuckerberg and Chan on track to put $50 billion into science

explore

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

How medical schools plan to diversify without affirmative action

Food makers to regulators: Ultra

Generate Biomedicines machine learning biotech raises $273M

PEPFAR is under serious threat — and so is global health

Traditional Chinese medicine benefits explored in new JAMA study

entertainment

leisure time

knowledge

hotspot